Judith M. Matthews
CIK 1734033 · Chief Financial Officer · last filed 2026-08-04
Judith M. Matthews is a Chief Financial Officer who has filed 12 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for ETON, was dated Aug 4, 2026. Across all open-market trades the lifetime net is −$136.2K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITRM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CHICAGO, IL 60606
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETON | Chief Financial Officer | — | $50.17 | — | $0 | 1 | 2026-08-04 |
| Iterum Therapeutics plc (ITRM) Delisted | Chief Financial Officer | 11,018 | $0.03 | $331 | -$136.2K | 11 | 2023-04-03 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | ETON | Grant (A) | — | $0 | EDGAR |
| 2023-04-03 | Iterum Therapeutics plc (ITRM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-14 | Iterum Therapeutics plc (ITRM) Delisted | Mixed | +3,783 | -$2.8K | EDGAR |
| 2022-03-15 | Iterum Therapeutics plc (ITRM) Delisted | Sell (S) | −63,340 | -$19.6K | EDGAR |
| 2022-03-15 | Iterum Therapeutics plc (ITRM) Delisted | Mixed | +52,868 | -$17.9K | EDGAR |
| 2021-06-25 | Iterum Therapeutics plc (ITRM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-15 | Iterum Therapeutics plc (ITRM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-27 | Iterum Therapeutics plc (ITRM) Delisted | Mixed | +28,632 | -$58.6K | EDGAR |
| 2020-10-02 | Iterum Therapeutics plc (ITRM) Delisted | Sell (S) | −56,130 | -$92.1K | EDGAR |
| 2019-02-19 | Iterum Therapeutics plc (ITRM) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.